Bicara Therapeutics Inc. (NASDAQ:BCAX)
| Market Cap | $650.95M-29.4% |
| Revenue (ttm) | $0 |
| Net Income | -$220.28M-81.3% |
| EPS | -$3.47-55.6% |
| Shares Out | 66.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 199,115.272 |
| Open | $9.76 |
| Previous Close | $9.98 |
| Day's Range | $9.45 - $10.13 |
| 52-Week Range | $7.87 - $30.99 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $31.57(+220.93%) |
| Earnings Date | Mar 29, 2027 |
About BCAX
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
6 firms rating BCAX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 29, 2027Earnings report
$BCAX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BCAX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BCAX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BCAX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BCAX Revenue by Segment
| Clinical operations and development | $27.06M | 55.36% |
| Manufacturing and process development | $16.11M | 32.95% |
| Professional fees | $4.79M | 9.81% |
| Research | $920.00K | 1.88% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BCAX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BCAX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BCAX
| VTIVanguard Morningstar Total Stock Market ETF | $31.20M |
| IWMiShares Russell 2000 ETF | $11.40M |
| XBIState Street SPDR S&P Biotech ETF | $9.80M |
| VXFVanguard Extended Market ETF | $9.08M |
| VTWOVanguard Russell 2000 ETF | $4.78M |
| IWOiShares Russell 2000 Growth ETF | $3.61M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from BCAX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Goldman Sachs downgrade and Wedbush price target cut ($33 to $24) dominate coverage, outweighing neutral operational updates.
Recent Insider Activity
Insider Score Trend Over Time
-39.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| SBIO | ALPS Medical Breakthroughs ETF | 0.44% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.36% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.32% |
| WCEO | Hypatia Women CEO ETF | 0.21% |
| CANC | Tema Oncology ETF | 0.19% |
| XBI | State Street SPDR S&P Biotech ETF | 0.11% |
| OPTZ | Optimize Strategy Index ETF | 0.08% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.05% |
| VMO.TO | Vanguard Global Momentum Factor ETF | 0.05% |
| VTWG | Vanguard Russell 2000 Growth ETF | 0.05% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.04% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.04% |
Weight is the stock’s share of each fund’s holdings.